Circulating 25-hydroxyvitamin D and prostate cancer survival.

BACKGROUND - Recent epidemiologic evidence suggests that higher circulating vitamin D does not protect against prostate cancer and, in fact, may increase the risk of developing this malignancy. However, few studies have examined the most clinically relevant outcome, prostate cancer mortality.

METHODS - We examined pre-diagnostic serum 25-hydroxy-vitamin D (25(OH)D) and prostate cancer survival in a cohort of 1,000 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. During 23 years of follow-up, 363 men died from their disease. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% CI of death from prostate cancer by season-specific quintile of 25(OH)D. Multivariable models were adjusted for age, physical activity, cigarettes per day, and family history of prostate cancer.

RESULTS - Men with higher serum 25(OH)D were less likely to die from their prostate cancer (Q5 vs. Q1 HR=0. 72, 95% CI=0. 52 - 0. 99, p-trend=0. 006). This finding was independent of stage or grade at diagnosis, and appeared restricted to men who survived longer (survived <3. 3 years: Q5 vs. Q1 HR=0. 95, 95% CI=0. 61 - 1. 50, p-trend=0. 53; survived ≥3. 3 years: Q5 vs. Q1 HR=0. 53, 95% CI=0. 34 - 0. 85, p-trend=0. 0002).

CONCLUSIONS - In this population of men diagnosed with prostate cancer, higher serum 25(OH)D years prior to diagnosis was associated with longer prostate cancer survival.

IMPACT - In light of inconsistent evidence regarding the role of vitamin D in the development of prostate cancer, the present findings regarding the most clinically relevant prostate cancer outcome, disease-specific mortality, could have important public health implications.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016 Jan 25 [Epub ahead of print]

Alison M Mondul, Stephanie J Weinstein, Kristin A Moy, Satu Mannisto, Demetrius Albanes

Department of Epidemiology, University of Michigan School of Public health Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. , National Cancer Institute. , Department of Chronic Disease Prevention, National Institute for Health and Welfare. , Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe